How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)
• By PharmAsia News
[Part 1 of this feature appeared Jan. 17 in PharmAsia News. Part 2 continues with the examination of China deals with Sanofi-Aventis' VP-Business Development Arjun Oberoi and Simcere President Yehong Zhang, who presented during the 29th annual J.P. Morgan Healthcare conference in San Francisco last week.]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
